Pharming Group N.V. reported total revenues of US$79.1 million for the first quarter of 2025, representing a 42% increase compared to the first quarter of 2024. This strong growth was driven by both RUCONEST and Joenja.
RUCONEST revenue increased by 49% to US$68.6 million compared to the first quarter of 2024, reflecting continued momentum and its position in the on-demand HAE market. Joenja (leniolisib) revenue increased by 9% to US$10.5 million, with accelerating patient uptake.
The company achieved an operating profit of US$1.1 million in the first quarter of 2025, a significant improvement from an operating loss in the prior year period. This indicates improving profitability and effective management of operational costs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.